title: [A Case of Multiple HCC with Vp2 and Vv3 Invasion Controlled by Multidisciplinary Treatment Including Surgery].
abstract: The prognosis of HCC with vascular invasion is dismal, but surgery is elected when the hepatic reserve is adequate. The case involved a 68-year-old male HCV carrier. A 10 cm diameter tumor occupying the central 2 segments of the liver and liver metastasis in the left lobe were detected. The patient was diagnosed with multiple HCC with severe vascular invasion of Vp2 and Vv3. The tumor shrunk dramatically after starting HAIC therapy with cisplatin and oral administration of sorafenib. A laparoscopic partial hepatectomy was performed for the viable lesion. The tumor showed almost complete coagulative necrosis. Multiple hepatic metastases were found 4 months after surgery, but the tumor was under control at 25 months after the first HAIC due to HAIC, oral administration of sorafenib, and RFA. An improved prognosis for multiple HCC with severe vascular invasion can be expected by performing multidisciplinary treatments including surgery.
authors.affiliation: Dept. of Hepato-Biliary-Pancreatic Surgery, Osaka City General Hospital.
authors.forename: Sota
authors.initials: S
authors.lastname: Deguchi
authors.forename: Tadashi
authors.initials: T
authors.lastname: Tsukamoto
authors.forename: Akishige
authors.initials: A
authors.lastname: Kanazawa
authors.forename: Sadatoshi
authors.initials: S
authors.lastname: Shimizu
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yamamoto
authors.forename: Akihiro
authors.initials: A
authors.lastname: Murata
authors.forename: Takayoshi
authors.initials: T
authors.lastname: Nakajima
authors.forename: Masayuki
authors.initials: M
authors.lastname: Sakae
authors.forename: Akiko
authors.initials: A
authors.lastname: Tachimori
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Tamamori
authors.forename: Atsushi
authors.initials: A
authors.lastname: Yamamoto
authors.forename: Toru
authors.initials: T
authors.lastname: Inoue
authors.forename: Yoshito
authors.initials: Y
authors.lastname: Yamashita
authors.forename: Yukio
authors.initials: Y
authors.lastname: Nishiguchi
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D017115:Catheter Ablation; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D006498:Hepatectomy; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000473:pathology / Q000628:therapy*; D008297:Male; D009361:Neoplasm Invasiveness; D009536:Niacinamide / Q000031:analogs & derivatives / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use; D011169:Portal Vein; D011379:Prognosis; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib; D002945:Cisplatin